EA201990988A1 - Антитела против chikv и пути их применения - Google Patents
Антитела против chikv и пути их примененияInfo
- Publication number
- EA201990988A1 EA201990988A1 EA201990988A EA201990988A EA201990988A1 EA 201990988 A1 EA201990988 A1 EA 201990988A1 EA 201990988 A EA201990988 A EA 201990988A EA 201990988 A EA201990988 A EA 201990988A EA 201990988 A1 EA201990988 A1 EA 201990988A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chikv
- antibodies
- ways
- application
- antibodies against
- Prior art date
Links
- 241001502567 Chikungunya virus Species 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306374 | 2016-10-20 | ||
| PCT/EP2017/076792 WO2018073387A1 (en) | 2016-10-20 | 2017-10-19 | Anti-chikv antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201990988A1 true EA201990988A1 (ru) | 2019-09-30 |
Family
ID=57590434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201990988A EA201990988A1 (ru) | 2016-10-20 | 2017-10-19 | Антитела против chikv и пути их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11286295B2 (enExample) |
| EP (1) | EP3529271A1 (enExample) |
| JP (3) | JP7181193B6 (enExample) |
| CN (2) | CN115873106A (enExample) |
| AR (1) | AR109857A1 (enExample) |
| CA (1) | CA3040842A1 (enExample) |
| EA (1) | EA201990988A1 (enExample) |
| IL (2) | IL266082B2 (enExample) |
| MA (1) | MA46562A (enExample) |
| TW (2) | TW202300515A (enExample) |
| UY (1) | UY37449A (enExample) |
| WO (1) | WO2018073387A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41517A (fr) * | 2015-04-14 | 2017-12-19 | Univ Vanderbilt | Neutralisation du virus du chikungunya à médiation par des anticorps |
| TW202300515A (zh) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| WO2019156758A2 (en) | 2018-01-05 | 2019-08-15 | Vanderbilt University | Antibody-mediated neutralization of chikungunya virus |
| KR102201261B1 (ko) * | 2019-05-15 | 2021-01-11 | 한국생명공학연구원 | 치쿤구니야 바이러스에 특이적인 단일클론 항체 및 이의 용도 |
| CN114656554B (zh) * | 2022-03-07 | 2023-05-23 | 中山大学 | 基孔肯雅热病毒e2蛋白的纳米抗体及其应用 |
| CN118956771A (zh) * | 2024-04-24 | 2024-11-15 | 华南农业大学 | 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用 |
| KR102830571B1 (ko) * | 2024-12-20 | 2025-07-09 | 대한민국(질병관리청 국립보건연구원장) | 치쿤구니아 바이러스 외피 재조합 단백질을 포함하는 치쿤구니아열 백신 조성물 |
| CN119841940B (zh) * | 2025-03-19 | 2025-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6018032A (en) | 1995-09-11 | 2000-01-25 | Kyowa Hakko Kogyo Co., Ltd. | Antibody against human interleukin-5-receptor α chain |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| AU7071598A (en) | 1997-04-10 | 1998-10-30 | Erasmus University Rotterdam | Diagnosis method and reagents |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| AU2005318171B2 (en) * | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| CA2545597A1 (en) | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| ES2742268T3 (es) | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| CN102015769B (zh) * | 2008-01-17 | 2014-12-10 | Irm责任有限公司 | 改进的抗-trkb抗体 |
| WO2009124312A2 (en) | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| HK1213481A1 (zh) | 2012-12-13 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | Dna抗体构建体及其使用方法 |
| WO2015010125A1 (en) | 2013-07-19 | 2015-01-22 | Integral Molecular, Inc. | Antibodies against chikungunya virus and uses thereof |
| MA41517A (fr) | 2015-04-14 | 2017-12-19 | Univ Vanderbilt | Neutralisation du virus du chikungunya à médiation par des anticorps |
| TW202300515A (zh) * | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
-
2017
- 2017-10-18 TW TW111134308A patent/TW202300515A/zh unknown
- 2017-10-18 TW TW106135643A patent/TWI778985B/zh active
- 2017-10-18 US US15/787,647 patent/US11286295B2/en active Active
- 2017-10-19 WO PCT/EP2017/076792 patent/WO2018073387A1/en not_active Ceased
- 2017-10-19 CN CN202211721154.0A patent/CN115873106A/zh active Pending
- 2017-10-19 IL IL266082A patent/IL266082B2/en unknown
- 2017-10-19 EA EA201990988A patent/EA201990988A1/ru unknown
- 2017-10-19 IL IL310834A patent/IL310834A/en unknown
- 2017-10-19 MA MA046562A patent/MA46562A/fr unknown
- 2017-10-19 JP JP2019521142A patent/JP7181193B6/ja active Active
- 2017-10-19 EP EP17794260.4A patent/EP3529271A1/en active Pending
- 2017-10-19 CN CN201780078371.3A patent/CN110088131B/zh active Active
- 2017-10-19 CA CA3040842A patent/CA3040842A1/en active Pending
- 2017-10-20 UY UY0001037449A patent/UY37449A/es unknown
- 2017-10-20 AR ARP170102933A patent/AR109857A1/es unknown
-
2022
- 2022-02-16 US US17/672,871 patent/US12227560B2/en active Active
- 2022-11-16 JP JP2022183022A patent/JP7664212B2/ja active Active
-
2024
- 2024-12-13 JP JP2024218402A patent/JP2025038079A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12227560B2 (en) | 2025-02-18 |
| CA3040842A1 (en) | 2018-04-26 |
| AR109857A1 (es) | 2019-01-30 |
| TWI778985B (zh) | 2022-10-01 |
| WO2018073387A1 (en) | 2018-04-26 |
| IL266082A (en) | 2019-06-30 |
| CN110088131B (zh) | 2022-12-06 |
| JP7181193B6 (ja) | 2022-12-13 |
| MA46562A (fr) | 2019-08-28 |
| JP7181193B2 (ja) | 2022-11-30 |
| JP2023015301A (ja) | 2023-01-31 |
| EP3529271A1 (en) | 2019-08-28 |
| UY37449A (es) | 2018-05-31 |
| JP2025038079A (ja) | 2025-03-18 |
| IL310834A (en) | 2024-04-01 |
| IL266082B1 (en) | 2024-03-01 |
| JP2019534001A (ja) | 2019-11-28 |
| US11286295B2 (en) | 2022-03-29 |
| IL266082B2 (en) | 2024-07-01 |
| US20180127487A1 (en) | 2018-05-10 |
| JP7664212B2 (ja) | 2025-04-17 |
| CN110088131A (zh) | 2019-08-02 |
| CN115873106A (zh) | 2023-03-31 |
| TW201827461A (zh) | 2018-08-01 |
| TW202300515A (zh) | 2023-01-01 |
| US20220275063A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201990912A1 (ru) | Анти-lag-3 антитела и их композиции | |
| EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
| EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201691877A1 (ru) | Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома | |
| EA201790174A1 (ru) | Антипролиферативные соединения и способы их применения | |
| CA3185706C (en) | Methods of treating fgf21-associated disorders | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| MX2022005256A (es) | Inhibidores de cd73. | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA201792561A1 (ru) | Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения | |
| EA202090414A1 (ru) | Соединения и их применение | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
| EA201890460A1 (ru) | Композиции и способы лечения и предотвращения нейродегенеративных расстройств | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| EA202190647A1 (ru) | Антитела к klrg1 | |
| MX394666B (es) | Dominios variables simples de inmunoglobulina contra proteina f de rsv. | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его |